# OnCo record nct05533775 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05533775/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05533775", "NCT05533775" ;
  schema:name "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu"@en ;
  schema:alternateName "iMATRIX GLO"@en ;
  schema:description "A phase 1/2 trial of Obinutuzumab, Glofitamab, Rituximab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05533775/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05533775> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-11-16" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> .